AT247, NovoRapid® and Fiasp® in Glucose Clamp Study


A Phase I, randomised, single-centre, double-blind, single-dose, three period, balanced cross over study in a glucose clamp setting. The study compares the pharmacodynamic, pharmacokinetic and safety characteristics of AT247, NovoRapid® and Fiasp® in male participants with type I diabetes mellitus.

Full Title of Study: “Phase I Single Dose, Randomised, Double-blind, Three-way Cross Over, Glucose Clamp Study Investigating the PK/PD and Safety of Arecor Ultra-rapid Insulin Aspart (AT247) in Comparison to NovoRapid® and Fiasp® in Participants With Type I Diabetes Mellitus (T1DM).”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 30, 2019


  • Biological: NovoRapid
    • Rapid acting prandial insulin aspart
  • Biological: Fiasp
    • Fast acting prandial insulin aspart
  • Biological: AT247
    • Ultra rapid acting prandial insulin aspart

Arms, Groups and Cohorts

  • Experimental: AT247
    • Single subcutaneous injection 0.3 U/Kg
  • Active Comparator: NovoRapid
    • Single subcutaneous injection 0.3 U/Kg
  • Active Comparator: Fiasp
    • Single subcutaneous injection 0.3 U/Kg

Clinical Trial Outcome Measures

Primary Measures

  • Area under the glucose infusion rate-time curve of insulin aspart
    • Time Frame: 0-60 minutes

Secondary Measures

  • Area under the serum insulin aspart concentration-time curve from 0-60 minutes
    • Time Frame: 0-60 minutes

Participating in This Clinical Trial

Inclusion Criteria include:

1. Diagnosis type I Diabetes Mellitus for at least 12 months

2. Receiving treatment with multiple daily insulin injections or insulin pump therapy for at least 12 months

3. Fasting C-peptide concentration ≤8.5% (≤69 mmol/mol) at screening

4. BMI 18.5-35.0 kg/m2

Exclusion Criteria include:

1. known or suspected hypersensitivity to Investigational Medicinal Products

2. clinically significant concomitant disease or abnormal lab values

3. supine systolic BP outside range 95-140 mmHg and/or diastolic BP greater than 90 mmHg

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Arecor Limited
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.